LAST UPDATE: 15.20
The European Medicines Agency (EMA) today approved the US Novavax vaccine against Covid-19, Nuvaxovid, and referred it to the Commission for final formal approval.
The vaccine will thus be the fifth, after those of Pfizer-BioNTech, Moderna, Oxford / AstraZeneca and Johnson & Johnson to be used to fight the coronavirus in the European Economic Area (27 EU plus Norway, Iceland, Liechtenstein).
Novavax will begin delivering doses of its COVID-19 vaccine to the European Union in January 2022, once it has been approved by the relevant European authorities, he said.
Earlier, Reuters reported that deliveries of the vaccine to the EU would begin in the first quarter of 2022.
The Novavax vaccine is not mRNA technology like those of Pfizer-BioNTech and Moderna, nor an adenovirus like those of Oxford / AstraZeneca and Johnson & Johnson, but it is protein-based.
According to the EMA, the data submitted by the company were excellent and prove the effectiveness, quality and safety of the preparation.
The side effects of the vaccine, according to the European body, were mild or moderate and are completed one to two days after vaccination.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
